{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:57:26Z","timestamp":1781164646543,"version":"3.54.1"},"reference-count":63,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Poly (ADP-ribose) polymerase (PARP1) has emerged as a promising therapeutic target in human breast cancer particularly in BRCA1\/2 mutation carriers where a synthetic lethal interaction leads to massive tumor cell death upon specific inhibitors\u2019 administration. Current clinically approved PARP inhibitors (Talazoparib and Olaparib) show outstanding therapeutic capabilities but suffer from severe side effects. Most importantly, some of them can cause life-threatening cardiotoxicity through hERG off-target effects. Here, we performed an extensive study to identify lead compounds with improved binding modes and favorable predicted pharmacokinetics using an integrated computational strategy. Methods: An artificial intelligence-driven drug design (AIDDISON\u2122 v2023) workflow was employed to search ultra-large chemical space libraries for active compounds, which were then optimized via computer-aided methods to form a PARP-Tailored Database (PTD). This database was then analyzed through a virtual screening workflow, molecular docking studies, molecular dynamics (MD) simulations, MM\/GBSA binding free energy calculations, DFT analysis and ADME\/Tox predictions using the Schr\u00f6dinger suite (v2023-2), MobaXterm v25.2, Gaussian 16.0, ProTox-3 and Pred-hERG v5.0 respectively. Results: Three compounds (1a\u20131c) were identified as promising candidates. Among them 1a appeared to be the most active compound with a favorable docking score (\u22129.488 kcal\/mol) that is not only higher than 1b and 1c but also higher than that of Talazoparib (\u22126.778 kcal\/mol). MD simulations of 1a\u20131c in the active site revealed an average RMSD of ~2.5\u20133.6 \u00c5 which is better compared to the parent Talazoparib (5.6 \u00c5). Interestingly, on the 250 ns extended MD study, 1a exhibited a slightly reduced RMSD between 2.4 and 3.2 \u00c5, whereas Talazoparib retained higher fluctuations of ~5 \u00c5 to 6 \u00c5. MM\/GBSA binding energy analysis indicated 1a to have better predicted binding affinity (\u221267.820 kcal\/mol), which is also better than Talazoparib (\u221263.734 kcal\/mol). DFT calculations showed good electronic properties and in silico ADMET studies also indicated 1a to have good drug-likeness and lower predicted hepatotoxicity and cardiotoxicity risk. Conclusions: These findings identify compound 1a as a promising lead, while compounds 1b and 1c remain viable candidates for further optimization. However, experimental validation is critical to confirm the predicted biological activity and safety profiles.<\/jats:p>","DOI":"10.3390\/ph19060914","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:57:17Z","timestamp":1781161037000},"page":"914","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Computational Evaluation of Novel PARP-1 Inhibitors for Breast Cancer: Docking, Molecular Dynamics, MM\/GBSA, DFT and ADMET Calculations"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8731-7032","authenticated-orcid":false,"given":"Charmy","family":"Twala","sequence":"first","affiliation":[{"name":"Department of Chemical Sciences, Faculty of Science, University of Johannesburg, Doornfontein Campus, Johannesburg 2094, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3011-6675","authenticated-orcid":false,"given":"Penny","family":"Govender","sequence":"additional","affiliation":[{"name":"Department of Chemical Sciences, Faculty of Science, University of Johannesburg, Doornfontein Campus, Johannesburg 2094, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8054-0071","authenticated-orcid":false,"given":"Ephraim","family":"Marondedze","sequence":"additional","affiliation":[{"name":"Department of Chemical Sciences, Faculty of Science, University of Johannesburg, Doornfontein Campus, Johannesburg 2094, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9058-1675","authenticated-orcid":false,"given":"Krishna","family":"Govender","sequence":"additional","affiliation":[{"name":"Department of Chemical Sciences, Faculty of Science, University of Johannesburg, Doornfontein Campus, Johannesburg 2094, South Africa"},{"name":"National Institute for Theoretical and Computational Sciences (NITheCS), Stellenbosch 7600, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly(ADP-ribose): Novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_2","first-page":"328","article-title":"PARP-1 and PARP-2: New players in tumour development","volume":"1","author":"Yelamos","year":"2011","journal-title":"Am. J. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.molmed.2008.02.003","article-title":"Toward specific functions of poly(ADP-ribose) polymerase-2","volume":"14","author":"Schreiber","year":"2008","journal-title":"Trends Mol. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/13102818.2020.1726208","article-title":"Investigation of the three-dimensional structure and interaction mechanism of poly(ADP-ribose) polymerase 4","volume":"34","author":"Unlu","year":"2020","journal-title":"Biotechnol. Biotechnol. Equip."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1111\/j.1742-4658.2005.04864.x","article-title":"Poly (ADP-ribose): The most elaborate metabolite of NAD+","volume":"272","year":"2005","journal-title":"FEBS J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrm3376","article-title":"New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs","volume":"13","author":"Gibson","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","article-title":"The PARP side of the nucleus: Molecular actions, physiological outcomes, and clinical targets","volume":"39","author":"Krishnakumar","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18877","DOI":"10.1074\/jbc.M110.105668","article-title":"The Zn3 domain of human PARP-1 functions in DNA-dependent synthesis activity and chromatin compaction","volume":"285","author":"Langelier","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1074\/jbc.M708558200","article-title":"A third zinc-binding domain of PARP-1 coordinates DNA-dependent enzyme activation","volume":"283","author":"Langelier","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2009.10.021","article-title":"Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective","volume":"46","author":"Sandhu","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/157489206775246430","article-title":"PARP-1 inhibitors in cancer chemotherapy","volume":"1","author":"Cepeda","year":"2006","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/ijc.33918","article-title":"PARP mediated DNA damage response, genomic stability and immune responses","volume":"150","author":"Zong","year":"2022","journal-title":"Int. J. Cancer."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.2147\/OTT.S184971","article-title":"Evidence to date: Talazoparib in the treatment of breast cancer","volume":"12","author":"Exman","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2217\/cer-2021-0097","article-title":"Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer","volume":"10","author":"McCrea","year":"2021","journal-title":"J. Comp. Eff. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/14756366.2015.1005011","article-title":"In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors","volume":"31","author":"Salmas","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-18-1891","article-title":"A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1\/2 mutations (ABRAZO)","volume":"25","author":"Turner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.sbi.2018.11.002","article-title":"PARP family enzymes: Regulation and catalysis of the poly(ADP-ribose) posttranslational modification","volume":"53","author":"Langelier","year":"2018","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","article-title":"Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors","volume":"13","author":"Hopkins","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Twala, C., Govender, P., and Govender, K. (2025). Computational chemistry advances in the development of PARP1 inhibitors for breast cancer therapy. Pharmaceuticals, 18.","DOI":"10.3390\/ph18111679"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.31925\/farmacia.2022.2.21","article-title":"Design, synthesis, biological evaluation and molecular docking of pyrrole-based compounds as antioxidant and MAO-B inhibitory agents","volume":"70","author":"Mateev","year":"2022","journal-title":"Farmacia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100251","DOI":"10.1074\/jbc.RA120.016573","article-title":"Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1","volume":"296","author":"Ryan","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12013-022-01075-3","article-title":"Talazoparib dual-targeting on poly(ADP-ribose) polymerase-1 and -16 enzymes as a therapeutic strategy in small cell lung cancer: Insight from biophysical computations","volume":"80","author":"Mgoboza","year":"2022","journal-title":"Cell Biochem. Biophys."},{"key":"ref_27","unstructured":"Schr\u00f6dinger, LLC. (2023). Schr\u00f6dinger Release 2023-2: QikProp, Schr\u00f6dinger, LLC."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5530\/ijper.51.1.15","article-title":"Molecular docking studies and in-silico ADMET screening of some novel oxazine substituted 9-anilinoacridines as topoisomerase II inhibitors","volume":"51","author":"Kalirajan","year":"2017","journal-title":"Indian J. Pharm. Educ. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/acs.jcim.3c01016","article-title":"AIDDISON: Empowering drug discovery with AI\/ML and CADD tools in a secure, web-based SaaS platform","volume":"64","author":"Rusinko","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acs.jmedchem.6b00990","article-title":"Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors","volume":"60","author":"Thorsell","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Adzhigirey","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Mateev, E., Kondeva-Burdina, M., Georgieva, M., Mateeva, A., Valkova, I., Tzankova, V., and Zlatkov, A. (2024). Synthesis, biological evaluation, molecular docking and ADME studies of novel pyrrole-based Schiff bases as dual acting MAO\/AChE inhibitors. Sci. Pharm., 92.","DOI":"10.3390\/scipharm92020018"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Twala, C., Malindisa, S., Munnik, C., Sooklal, S., and Ntwasa, M. (2025). Ezetimibe anticancer activity via the p53\/Mdm2 pathway. Biomedicines, 13.","DOI":"10.3390\/biomedicines13010195"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1103\/PhysRevA.31.1695","article-title":"Canonical dynamics: Equilibrium phase-space distributions","volume":"31","author":"Hoover","year":"1985","journal-title":"Phys. Rev. A"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"184101","DOI":"10.1063\/5.0193281","article-title":"Novel barostat implementation for molecular dynamics","volume":"160","author":"Janek","year":"2024","journal-title":"J. Chem. Phys."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1063\/1.470117","article-title":"A smooth particle mesh Ewald method","volume":"103","author":"Essmann","year":"1995","journal-title":"J. Chem. Phys."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1021\/jm060522a","article-title":"Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring","volume":"49","author":"Lyne","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_39","unstructured":"Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Scalmani, G., Barone, V., Mennucci, B., and Petersson, G.A. (2009). Gaussian 09, Revision D.01, Gaussian, Inc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9824","DOI":"10.1039\/D3RA01154B","article-title":"Density functional theory computation of intermolecular interactions of Al2C24 and Al2Mg12O12 quantum dots with glycine tripeptide","volume":"13","author":"Mohammadi","year":"2023","journal-title":"RSC Adv."},{"key":"ref_41","unstructured":"Cramer, C.J. (2013). Essentials of Computational Chemistry: Theories and Models, Wiley. [2nd ed.]."},{"key":"ref_42","first-page":"109159","article-title":"Structural, electronic, and thermodynamic characterization with spectroscopic, topological, reactivity, and molecular docking studies of diallyl sulfide","volume":"129","author":"Neupane","year":"2025","journal-title":"J. Mol. Graph. Model."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101709","DOI":"10.1016\/j.rechem.2024.101709","article-title":"Computational analysis and biological investigation of cellulose acetate: PED, HOMO\u2013LUMO, MEP and molecular docking","volume":"10","author":"Shafieyoon","year":"2024","journal-title":"Results Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1126\/science.218.4574.747","article-title":"Role of frontier orbitals in chemical reactions","volume":"218","author":"Fukui","year":"1982","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Mahmood, N., Rasool, N., Ikram, H.M., Hashmi, M.A., Mahmood, T., Zubair, M., Ahmad, G., Rizwan, K., Rashid, T., and Rashid, U. (2018). Synthesis of 3,4-biaryl-2,5-dichlorothiophene and theoretical exploration as nonlinear optical materials. Symmetry, 10.","DOI":"10.3390\/sym10120766"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.9734\/jpri\/2021\/v33i46B32909","article-title":"Design, docking, ADMET and PASS prediction studies of novel chromen-4-one derivatives as prospective anticancer agents","volume":"33","author":"Ratra","year":"2021","journal-title":"J. Pharm. Res. Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/00387010.2021.1932964","article-title":"Molecular structure, vibrational spectroscopic and frontier molecular orbital analysis of anticancer drug derivatives","volume":"54","author":"Usha","year":"2021","journal-title":"Spectrosc. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6735232","DOI":"10.1155\/2020\/6735232","article-title":"Biological activity of selected compounds from Annona muricata seed as antibreast cancer agents: A theoretical study","volume":"2020","author":"Oyebamiji","year":"2020","journal-title":"J. Chem."},{"key":"ref_49","unstructured":"Dorlus, T.A. (2025). In Silico Analysis of Donor\u2013Acceptor Based \u03c0-Conjugated Compounds for Organic Solar Materials: A DFT\/TD-DFT Study, Jackson State University."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"174101","DOI":"10.1063\/1.3491272","article-title":"On Koopmans\u2019 theorem in density functional theory","volume":"133","author":"Tsuneda","year":"2010","journal-title":"J. Chem. Phys."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.saa.2014.08.054","article-title":"Molecular structure, vibrational spectral assignments, HOMO\u2013LUMO and thermodynamic properties of substituted cyclohexanol derivatives","volume":"137","author":"Arivazhagan","year":"2015","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.saa.2014.04.041","article-title":"The spectroscopic (FT-IR, FT-Raman and NMR), first order hyperpolarizability and HOMO\u2013LUMO analysis of 2-mercapto-4 (3H)-quinazolinone","volume":"129","author":"Prabavathi","year":"2014","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF02708340","article-title":"Chemical hardness and density functional theory","volume":"117","author":"Pearson","year":"2005","journal-title":"J. Chem. Sci."},{"key":"ref_54","first-page":"417","article-title":"Evaluating the efficacy of different SARS-CoV-2 drug targets using the topo-geometrical superposition algorithm, molecular docking and chemical reactivity frameworks","volume":"6","author":"Zinhumwe","year":"2025","journal-title":"J. Biomed. Res. Environ. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"123775","DOI":"10.1016\/j.jorganchem.2025.123775","article-title":"Synthesis, computational screening, antidiabetic, antibacterial, DNA, pharmacokinetics\/ADMET analysis and molecular docking studies of pentamethylcyclopentadienyl ruthenium(III) carboxylate complex","volume":"1038","author":"Bibi","year":"2025","journal-title":"J. Organomet. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"131419","DOI":"10.1016\/j.matchemphys.2025.131419","article-title":"Lasso regression with molecular descriptors predicts natural product adsorption onto graphene oxide-derived adsorbents","volume":"347","author":"Guo","year":"2025","journal-title":"Mater. Chem. Phys."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"143672","DOI":"10.1016\/j.molstruc.2025.143672","article-title":"Eco-friendly synthesis, spectroscopic, in vitro anticancer and antimicrobial activity of benzimidazole derivatives with in silico ADME and molecular modeling study","volume":"1350","author":"Ram","year":"2025","journal-title":"J. Mol. Struct."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Dalgic, S.S., and Kandemirli, F. (2025, January 15\u201317). Comparison of the electron donor\u2013acceptor and sensing capacity of selected CNTs in drug delivery applications. Proceedings of the Technical University of Sofia, Plovdiv, Bulgaria.","DOI":"10.47978\/TUS.2024.74.03.001"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"123802","DOI":"10.1016\/j.jorganchem.2025.123802","article-title":"Synthesis, physicochemical characterization, exploration of biological potential and DFT study of di- and tri-organotin(IV) carboxylate derivatives","volume":"1039","author":"Noureen","year":"2025","journal-title":"J. Organomet. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e1735","DOI":"10.1002\/wcms.1735","article-title":"Unveiling drug discovery insights through molecular electrostatic potential analysis","volume":"14","author":"Haritha","year":"2024","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s44371-025-00467-7","article-title":"Chemoinformatics profiling of Annona muricata-derived compounds targeting COX-2 in breast cancer","volume":"3","author":"Mbayo","year":"2026","journal-title":"Discov. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"W513","DOI":"10.1093\/nar\/gkae303","article-title":"ProTox 3.0: A webserver for the prediction of toxicity of chemicals","volume":"52","author":"Banerjee","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1021\/acs.chemrestox.3c00400","article-title":"Enhancing hERG risk assessment with interpretable classificatory and regression models","volume":"37","author":"Sanches","year":"2024","journal-title":"Chem. Res. Toxicol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/914\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:06:01Z","timestamp":1781161561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":63,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ph19060914"],"URL":"https:\/\/doi.org\/10.3390\/ph19060914","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}